BAP1-deficient tumors exhibited a significant increase in phosphorylated IRF7 protein levels following treatment with JX-594, rather than treatment with the STING agonist, suggesting a relationship between JX-594 and STING expression and activity in ccRCC cells. Here, BAP1 is linked to nonpapillary renal cell carcinoma.